Danofloxacin (Advocin) reduces the spread of contagious bovine pleuropneumonia to healthy in-contact cattle.
Contagious bovine pleuropneumonia (CBPP), caused by Mycoplasma mycoides subsp. mycoides SC (MmmSC), is one of the most important diseases of cattle in Sub-Saharan Africa. The live T1/44 vaccine is normally used for its control but produces only transient protection and gives rise to adverse reactions. The present study evaluated the efficacy of danofloxacin (2.5% Advocintrade mark, Pfizer Ltd.) for the treatment of naturally infected cattle and in the prevention of CBPP transmission to in-contact cattle. Adult cattle, taken from a natural outbreak, were placed into two groups of 10 animals and kept on a research farm in paddocks 50m apart. One group was treated with 2.5mg/kg danofloxacin on days 0, 1 and 2; the other group were saline treated. On day 2, 10 CBPP-free, seronegative cattle were placed in contact with each of the two groups. All cattle were monitored for 3.5 months. No differences were seen in clinical improvement of the CBPP-affected cattle treated with danofloxacin compared with the untreated CBPP-affected cattle with approximately half of each group being withdrawn because of CBPP or showing CBPP lesions at post mortem examination. Clinical scores of the two groups were also similar. However cattle kept in contact with the danofloxacin-treated CBPP-affected animals showed significantly fewer lesions, less mortality and fewer animals were seropositive (P<0.02) and had reduced clinical scores (P<0.001) compared to cattle kept in contact with untreated CBPP-affected cattle. MmmSC was also isolated from fewer contact controls kept with the treated group. These findings could have important implications for the control of CBPP in Africa.
Huebschle
Otto J B
OJ
Central Veterinary Laboratory, Windhoek, Namibia.
Ayling
Roger D
RD
Godinho
Kevin
K
Lukhele
Obed
O
Tjipura-Zaire
Georgina
G
Rowan
Tim G
TG
Nicholas
Robin A J
RA
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000517:prevention & control* / Q000635:transmission; D024841:Fluoroquinolones / Q000494:pharmacology / Q000627:therapeutic use*; D006262:Health; D009176:Mycoplasma mycoides; D011002:Pleuropneumonia, Contagious / Q000188:drug therapy* / Q000517:prevention & control* / Q000635:transmission; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000517:prevention & control / Q000635:transmission / Q000662:veterinary*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C068581:danofloxacin